GB2284154A - Anti-aging compositions for cosmetic use - Google Patents

Anti-aging compositions for cosmetic use Download PDF

Info

Publication number
GB2284154A
GB2284154A GB9420224A GB9420224A GB2284154A GB 2284154 A GB2284154 A GB 2284154A GB 9420224 A GB9420224 A GB 9420224A GB 9420224 A GB9420224 A GB 9420224A GB 2284154 A GB2284154 A GB 2284154A
Authority
GB
United Kingdom
Prior art keywords
agent
cosmetic composition
skin
cosmetic
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9420224A
Other versions
GB9420224D0 (en
Inventor
Francoise Lataste
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires de Biologie Vegetale Yves Rocher SA
Original Assignee
Laboratoires de Biologie Vegetale Yves Rocher SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires de Biologie Vegetale Yves Rocher SA filed Critical Laboratoires de Biologie Vegetale Yves Rocher SA
Publication of GB9420224D0 publication Critical patent/GB9420224D0/en
Publication of GB2284154A publication Critical patent/GB2284154A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14Liposomes; Vesicles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70Biological properties of the composition as a whole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/78Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

Compositions comprise a combination of an anti-elastase agent, an anti-collagenase agent and an agent that stimulates collagen III synthesis in an cosmetic excipient. Anti elastase agents may be tannin, oleic acid, uvaol or alpha -2 macroglobulin. The anti collagenases may be EDTA, L-cysteine, metal ions or mercaptans. Collagen III synthesis stimulators may be a fatty acid ester of ascorbic acid or hydroxyproline etc.

Description

COSMETIC COMPOSITION AND BEAUTY TREATMENT METHOD COUTERACTING SKIN AGEING The present invention relates to a cosmetic composition comprising an effective amount of a combination of three types of substances displaying different activities.
The present invention also relates to a beauty treatment method counteracting skin aging.
In order to alleviate the phenomenon of skin aging, cosmetology has developed various cosmetic compositions.
These compositions can contain nutrients for the cells (amino acids, sugars, vitamins, etc), constituent components of the skin (collagen, elastin, essential fatty acids, factors, NNF, etc) and agents affording protection against the external environment (free-radical scavengers, film-forming agents, anti-WA screening agents, etc).
Since the activity of these different cosmetic compositions is relatively short-lived and only slightly effective, it hence proved useful to develop cosmetic compositions displaying lasting and effective activity.
The authors of the present invention discovered, surprisingly, that the combination of an effective amount of three types of known substances had a synergistic activity for counteracting skin aging, in comparison with the activity of the substances taken separately.
Thus, the present invention relates to a cosmetic composition, characterized in that it comprises an effective amount of a combination of an anti-elastase agent, an anti-collagenase agent and an agent that stimulates collagen III synthesis, in a suitable cosmetic excipient.
As an agent that stimulates collagen synthesis, it is possible to use the products described in Patent Application EP-0,537,092 and in Patent Application FR 93/05,050. These products comprise, as an agent that stimulates collagen III synthesis, fatty esters of ascorbic acid, and in particular its palmitate., the palmitate of collagen hydrolysate and the fatty esters of hydroxyamino acids such as hydroxyproline, and more especially its palmitate.
These agents are contained in vesicular carriers which can be liposomes obtained, for example, according to the process described in FR-A-2,649,335 or nanospheres.
Vesicles comprising phospholipids and hydroxyproline palmitate in combination with cholesterol are especially preferred.
The single-membrane phospholipid structure of these "carriers is rhombohedral. They thus afford a surface/volume ratio greater than that of spherical carriers.
This composition is described as having a stimulatory activity that triggers. a non-dose-dependent response by fibroblasts, arousing in them their capacity to synthesize collagen III.
This stimulatory activity is due to the rhombohedral structure and to the mixture of the three substances in an effective amount. Thus, in carriers of phospholipid type, the phospholipids (lecithin) represent 70 to 95% by weight on a dry basis, cholesterol represents 1 to 15% by weight on a dry basis and the amino acid/alcohol dipalmitate 1 to 15% by weight on a dry basis of the composition.
This composition counteracts the phenomenon of skin aging.
As regards the preparation of the composition that stimulates collagen III synthesis, it is necessary to work in a sterile medium with equipment which is also sterilized. The active principles, in well-defined proportions, are mixed according to a precise order.
The anti-collagenase agent can be a chelating agent such as EDTA, L-cysteine, metals such as Peck, CuZ and Zn++ and mercaptans, it being possible for the anticollagenases to be of natural origin, plant origin and serum origin (ss1-anti-collagenase, a2-macroglobulin).
Reference may be made in this connection to "Handbook of Enzyme Inhibitors", 2nd Edition, A and B by Helmward Zollner, pp. 131 to 135.
The anti-elastase agent may be chosen from antielastases of plant origin such as tannin, oleic acid, the triterpene uvaol and cucurbita maxima; anti-elastases of fungal origin such as cephalosporin; anti-elastases of serum origin such as a2-macroglobulin; and anti-elastases of natural origin, and the like (propionylamino acid derivatives, thiazolidinecarboxylic acid derivatives).
Reference may be made in this connection to "Handbook of Ellzyme Inhibitors", 2nd Edition, A and B by Helmward Zollner, pp. 195 to 199).
Preferably, the combination of the anti-elastase and anti-collagenase agents and the agent that stimulates collagen III synthesis represents 0.3 to 10% by weight of the composition, and the different agents are present in the proportion of 0.1 to 5% by weight of the composition.
The appropriate cosmetic excipients are, of course, chosen according to whether the compositions are in the form of a cream, a fluid emulsion or a gel.
The activity of the cosmetic compositions of the present invention was tested in comparison with that of compositions comprising the three agents separately.
The tests consist in examining the pattern of micro-depressions (PmD) of the skin by computer-aided vision (CAV) and measuring the depth of the wrinkle, as well as measuring skin firmness.
The objective of the evaluation of the structural components of the micro-contours of the skin is to evaluate in man the effect of a cosmetic or body hygiene product on the structural components of the microcontours of the skin, using a quantification by CAV.
The tests are carried out on healthy volunteer subjects, informed beforehand of the nature of the experiment and who have given their informed consent.
Precision imPression of the skin: - XANTOPRENs VL (BAYER), low viscosity material based on silicone crosslinking by condensation.
- OPTOSILs - XANTOPRENQ ACTIVATOR (BAYER), liquid activator.
- Farbkonzentrat BLAU RL, blue dye.
Image analyser: This comprises: - An IVC 800 BC video camera (SONY) equipped with an MD MACRO 50 mm 1:3.5 objective; 8 = 55 mm (MINOLTA) and connected to a monitor (SONY); - An IBM PC compatible microcomputer; - An image analysis techniques training software package, MICROMORPH (Centre de Morphologie Mathmatique de l'Ecole des Nines de Paris (Mathematical Morphology Centre of Paris School of Miners3).
Equipment: - Binocular magnifier (NIKON).
The method is as follows: The exploration are a varies in accordance with the indication for which the product is tested. Ana comical landmarks are chosen in order to define the area carefully. In the present case, the skin of the face is the region which will be tested.
The impression mixture is prepared at the time of use: 2.5 grams of XANTOPRENS VL and 45 milligrams of Farbkonzentrat BIAU RL are mixed with 3 drops of OPTOSIL - XANTOPREN ACTIVATOR for 30 seconds.
Impression-taking is performed before treatment on unwashed skin which has not received any product for at least 8 hours.
Subjects are settled comfortably, and the plane of inclination of the head is determined. Using a spatula, the impression mixture is rapidly applied in a uniform layer to the exploration area. The surface covered is approximately 25 to 30 cm2. The setting time in order to permit polymerization is approximately 2 minutes. Detachment of the impression takes place from the upper edge, in the direction of the hairs and the down.
Impression-taking on treated skin is done as an immediate effect, either 15 minutes after application of the product and/or after a frequency and a time of application which are defined by the instigator of the experiment.
Impressions are examined using a binocular magnifier at a magnification of 15 and/or 20. A carefully identified area is stored in the computer memory and quantification of the different structural components of the micro-contours of the skin, pattern of surface micro-depressions (PmD) and polygons, is done by computer-aided vision.
The results of the effect of the products tested on the changes in the structural components of the microcontours of the skin are expressed by: - The differences between the integrals of the structural components of the micro-contours of the skin, pattern of surface micro-depressions (PmD) and polygons, before and after treatment.
The changes are calculated according to the formula: Integral after treatment - Integral before treatment x 100 Integral before treatment - Clinical appraisal of the structural components of the micro-contours of the skin observed with the binocular magnifier before and after treatment.
The measurement of skin firmness has as its principle suction of the epidermis with a probe under a constant partial vacuum which is adjustable from 0 to 500 mbar depending on the areas to be studied.
The movement of the epidermis in the probe is measured by two optical lenses.
The rise of the epidermis corresponds to the extensibility, its fall to the tonicity.
The ratio of the tonicitv extensibility measurements is calculated by computer and evaluates the firmness, between 0 and 1.
The equipment comprises: - 1 SEM 474 firmness gauge - 1 AMSTRAD 1640 SD computer - 1 PANASONIC KX P1124 printer The protocol consists in performing, after adjusting the partial vacuum in mbar and the time of rise and release of the epidermis in the probe, a series of three measurements on a particular area before and after treatment, under identical conditions.
The two tests described above gave results which show that the combination of an effective amount of the anti-elastase and anti-collagenase agents and the agent that stimulates collagen III synthesis has a synergistic effect for counteracting skin aging, compared to the effect obtained under the same conditions with the three agents tested separately.
The subject of the present invention is also a beauty treatment method counteracting skin aging, characterized in that an effective amount of a cosmetic composition according to the present invention is applied to the skin.
In the different formulations which follow, the expression "firmness complex" means "combination of the three types of substances according to the invention", that is to say from 0.1 to 5% of each of the agents, namely an anti-elastase agent, an anti-collagenase agent and an agent that stimulates collagen III synthesis.
Examples of typical cosmetic compositions are the following: EXAMPLE 1 Care Cream Demineralized water qs Ce/C1O Triglyceride 1 to 10 % Glyceryl trilaurate 1 to 5 % Silicone 1 to 8 % Glucate SSe 1 to 15 % Stearic acid 1 to 10 % Cetyl alcohol 1 to 8 % Polyacrylic acid 1 to 5 % Triethanolamine 0.1 to 1 % Preservatives 0.3 to 1 % Firmness complex 0.3 to 10 % EXAMPLE 2 Fluid Emulsion Demineralized water gs Propylene glycol 1 to 3 % Glycerol 1 to 8 % PCA 0.05 to 1 % L-Lysine 0.2 to 1 % Na, EDTA 0.01 to 0.1 % Carbopol 9419 0.1 to 2 % Stearoxydimethicone 0.5 to 3 % Ethylhexyl cocoate 5 to 8 % Mineral oil 1 to 15 % Arlacel 60e 1 to 8 % Brij 58e 0.1 to 1 % Preservatives 0.3 to 1 % Firmness complex 0.3 to 10 % EXAMPLE 3 Gel Demineralized water gep Glycerol 5 to 20 % Na, EDTA 0.01 to 0.5 % Sepigel 305 Preservatives 0.3 to 1 % Firmness complex 0.3 to 10 % Example of prenaration of the fluid emulsion: A gel is prepared by introducing Carbopol 941 powder (0.1 to 2% by weight) with vigorous agitation into cold water, which is vortexed.
Separately, an aqueous phase is prepared by mixing the components propylene glycol (1 to 3% by weight), glycerol (1 to 8%), PCA (0.05 to 1%), L-lysine (0.2 to 1%), Na4 EDTA (0.01 to 0.1%) and preservatives (0.3 to 1%). The abovementioned mixture is then heated to 70-750C with agitation and the gel prepared above is thereafter introduced into the aqueous phase.
The fatty phase is prepared by heating the collective constituents stearoxydimethicone (0.5 to 3%), ethylhexyl cocoate (5 to 8%), mineral oil (1 to 15%), Arlacel 60 (1 to 8%) and Brij 58 (0.1 to 1%) to 75-800C. The fatty phase is then drawn into the aqueous phase with the gel. A vacuum is applied. The mixture is allowed to cool to 350C in order to introduce the "firmness complex" (0.3 to 10% by weight). The mixture is agitated and allowed to cool under vacuum. At 250C, tie agitation is stopped and the preparation is checked.

Claims (8)

1. Cosmetic composition, cdmprising an effective amount of a combination of an anti-elastase agent, an anti-collagenase agent and an agent that stimulates collagen III synthesis, in a suitable cosmetic excipient.
2. Cosmetic composition according to Claim 1, in which the combination of an antielastase agent, a-1 anti-collagenase agent and an agent that stimulates collagen III synthesis represents 0.3 to 10% by weight of the composition.
3. Cosmetic composition according to Claims 1 and 2, in which the anti-elastase agent is present in the proportion of 0.1 to 5% by weight of the composition.
4. Cosmetic composition according to Claims 1 and 2, in which the anti-collagenase agent is present in the proportion of 0.1 to 5% by weight of the composition.
5. Cosmetic composition according to Claims 1 and 2, in which the agent that stimulates collagen III synthesis is present in the proportion of 0.1 to 5% by weight of the composition.
6. Cosmetic composition according to any one of the preceding claims, in the form of a cream, a fluid emulsion ot a gel.
7. Beauty treatment method counteracting skin aging, in which an effective amount of a cosmetic composition according to Claims 1 to 6 is applied to the skin.
8. A cosmetic composition substantially as hereinbefore described with reference to Examples 1 to 3.
GB9420224A 1993-10-08 1994-10-07 Anti-aging compositions for cosmetic use Withdrawn GB2284154A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9312040A FR2710839B1 (en) 1993-10-08 1993-10-08 Cosmetic composition and aesthetic treatment method opposing aging of the skin.

Publications (2)

Publication Number Publication Date
GB9420224D0 GB9420224D0 (en) 1994-11-23
GB2284154A true GB2284154A (en) 1995-05-31

Family

ID=9451687

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9420224A Withdrawn GB2284154A (en) 1993-10-08 1994-10-07 Anti-aging compositions for cosmetic use

Country Status (4)

Country Link
ES (1) ES2072230B1 (en)
FR (1) FR2710839B1 (en)
GB (1) GB2284154A (en)
IT (1) IT1267465B1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1005333A1 (en) * 1997-02-25 2000-06-07 The University Of Michigan Methods and compositions for preventing and treating chronological aging in human skin
EP1163900A1 (en) * 1998-11-05 2001-12-19 Protease Sciences, Incorporated Cosmetic compositions containing human type serine protease inhibitors
WO2002096291A1 (en) * 2001-05-30 2002-12-05 Unilever Plc Cosmetic product with a device for evaluating its efficacy and method of using the latter
AU2002304622B2 (en) * 2001-05-30 2004-12-16 Unilever Plc Wrinkle indicator tape strip and method of using the same
US8895034B2 (en) 2011-11-02 2014-11-25 Mark K Bennett Collagen production compound
US10155733B2 (en) 2015-04-28 2018-12-18 Conopco, Inc. N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same
US10307355B2 (en) 2015-04-28 2019-06-04 Conopco, Inc. N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2746316B1 (en) * 1996-03-19 1998-06-12 Guerlain NEW COSMETOLOGICAL OR DERMATOLOGICAL COMPOSITIONS
JP5725864B2 (en) * 2010-08-06 2015-05-27 株式会社 資生堂 Elastase inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2683720A1 (en) * 1991-11-15 1993-05-21 Jouvance Daniel Composition for cosmetic use containing particles of a gelled substance

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2546164B1 (en) * 1983-05-16 1987-07-17 Centre Nat Rech Scient NOVEL PEPTIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ELASTASE INHIBITORS
DE3788300D1 (en) * 1986-05-14 1994-01-13 Floersheim Georg L Pharmaceutical preparation for preventing free radical damage to living cells or for increasing the effectiveness of organic sulfur compounds and method for increasing the lifespan of isolated organs.
FR2611140B1 (en) * 1987-02-20 1991-02-22 Lamaison Jean Louis PROCESS FOR OBTAINING TANNIC PRINCIPLES OF PLANT ORIGIN, COSMETOLOGICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING THE PURIFIED TANNIC PRINCIPLE OBTAINED ACCORDING TO THE PROCESS
FR2666226B1 (en) * 1990-08-30 1994-10-28 Jean Noel Thorel PROTECTIVE SKIN COMPOSITION.
FR2670672B1 (en) * 1990-12-21 1995-02-03 Sanofi Sa COSMETIC COMPOSITIONS BASED ON PLANT EXTRACTS.
EP0537092A1 (en) * 1991-10-08 1993-04-14 Patrinove Societe Civile Infracellular vesicular vectors and their application in cosmetic and medical compositions and culture media

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2683720A1 (en) * 1991-11-15 1993-05-21 Jouvance Daniel Composition for cosmetic use containing particles of a gelled substance

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WPI Accession No. 93-260440/33 & FR 2683720 A1 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1005333A1 (en) * 1997-02-25 2000-06-07 The University Of Michigan Methods and compositions for preventing and treating chronological aging in human skin
EP1005333A4 (en) * 1997-02-25 2001-03-14 Univ Michigan Methods and compositions for preventing and treating chronological aging in human skin
EP1163900A1 (en) * 1998-11-05 2001-12-19 Protease Sciences, Incorporated Cosmetic compositions containing human type serine protease inhibitors
WO2002096291A1 (en) * 2001-05-30 2002-12-05 Unilever Plc Cosmetic product with a device for evaluating its efficacy and method of using the latter
AU2002304622B2 (en) * 2001-05-30 2004-12-16 Unilever Plc Wrinkle indicator tape strip and method of using the same
AU2002312889B2 (en) * 2001-05-30 2004-12-16 Unilever Plc Cosmetic product with a device for evaluating its efficacy and method of using the latter
US6875444B2 (en) 2001-05-30 2005-04-05 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Wrinkle indicator tape strip
US6926904B2 (en) 2001-05-30 2005-08-09 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Cosmetic product with proof device
US8895034B2 (en) 2011-11-02 2014-11-25 Mark K Bennett Collagen production compound
US10155733B2 (en) 2015-04-28 2018-12-18 Conopco, Inc. N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same
US10307355B2 (en) 2015-04-28 2019-06-04 Conopco, Inc. N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same

Also Published As

Publication number Publication date
ITTO940790A0 (en) 1994-10-07
FR2710839A1 (en) 1995-04-14
IT1267465B1 (en) 1997-02-05
ITTO940790A1 (en) 1996-04-07
ES2072230A1 (en) 1995-07-01
GB9420224D0 (en) 1994-11-23
FR2710839B1 (en) 1995-12-08
ES2072230B1 (en) 1996-02-01

Similar Documents

Publication Publication Date Title
EP0633764B1 (en) Skin care method and composition
RU2120794C1 (en) Cosmetic composition for protecting, nourishing and/or firming of superficial and more deep integument and method for protecting, nourishing and/or firming the skin
EP0633765B1 (en) Skin care method and composition
US3957971A (en) Moisturizing units and moisturizing compositions containing the same
EP0739195B1 (en) Skin tanning compositions
RU2125442C1 (en) Composition for skin care and method of skin care
EP0684040B1 (en) Skin treatment composition
US20020137691A1 (en) Pharmaceutical compositions and methods for reducing the appearance of cellulite
EP0957888A1 (en) Lip treatment containing live yeast cell derivative
CN101677912A (en) Gel useful for the delivery of cosmetic active ingredients
CN110882186A (en) Composition with effects of controlling oil, shrinking pores and relieving and preparation method thereof
JP2013521251A (en) Beauty composition
US20220160607A1 (en) Anti-aging cosmetic compositions
GB2284154A (en) Anti-aging compositions for cosmetic use
CN110279643A (en) A kind of reparation efficacy and the preparation method and application thereof
JP5105962B2 (en) Cornified envelope formation / maturation promoter
JP3687747B2 (en) Topical skin preparation
US11382858B2 (en) Active ingredient obtained from Nymphaea alba flowers
DE69533714T2 (en) Lactate dehydrogenase inhibitors in cosmetic products
KR20120061048A (en) Use of isoleucine n-hexadecanoyl as a "volumizing" and/or "plumping" agent for human skin
US5882661A (en) Composition and method for topical application to skin, hair and nails
JPH11180851A (en) Skin cosmetic
JPH0967229A (en) Beautifully whitening cosmetic
WO2020175703A1 (en) Aqueous dispersion for cosmetic preparation, cosmetic preparation composition, and method for producing cosmetic preparation
JPH09255546A (en) Skin preparation for external use

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)